A powerful approach

We are leveraging the genetic principle of synthetic lethality and the power of our state-of-the-art CRISPR-based target discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of programs for genetically defined subsets of cancers with limited treatment options.

Development Pipeline

Patient Selection
Clinical Trials
Anticipated Milestones
MTAP-del cancers
Phase 1/2
Phase 3
Additional clinical data in 2024
Phase 1/2
Patients: MTAP-del cancers
Anticipated Milestones: Additional clinical data in 2024
Development Pathway

Our Phase 1/2 first-in-human trial to evaluate TNG908 in patients with MTAP-deleted tumors is being conducted in two parts. The dose escalation phase will evaluate safety, efficacy, pharmacokinetics and pharmacodynamics in patients with locally advanced or metastatic cancer of any histology with an MTAP deletion. After determining the optimally-effective dose for TNG908, we will further evaluate safety and efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor (MPNST – a rare sarcoma), non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma.  In parallel, we will enroll a histology-agnostic arm to evaluate all other tumor types with MTAP deletion. Given that MTAP deletion occurs in approximately 10-15% of human cancers, we may open other histology-specific arms based on activity observed in the trial.

The FDA cleared the Investigational New Drug (IND) application for TNG908 in January 2022, and granted Fast Track Designation to TNG908. Additionally, the FDA granted Orphan Drug Designation for the treatment of MPNST and malignant glioma, including glioblastoma, with TNG908. Patients are being actively enrolled in the Phase 1/2 clinical trial. We expect to provide an update on the ongoing dose escalation portion of the trial, focusing on the proof-of-mechanism, in the second quarter of 2023.

MTAP-del cancers
First patient dose expected mid-2023
Phase 1/2
Patients: MTAP-del cancers
Anticipated Milestones: First patient dose expected mid-2023
Development Pathway

The clinical development path for TNG462 is expected to be similar to TNG908, evaluating safety and efficacy in multiple tumor types in a Phase 1/2 clinical trial. Glioblastoma will be excluded from the Phase 1/2 trial as TNG462 does not cross the blood-brain barrier in preclinical models. We expect to initiate a Phase 1/2 clinical trial in mid-2023. We are planning to fully evaluate both TNG908 and TNG462 in clinical trials.

STK11-mut cancers
Clinical trial start 2H 2023
Phase 1/2
Patients: STK11-mut cancers
Anticipated Milestones: Clinical trial start 2H 2023
Development Pathway

The TNG260 clinical development plan will be among the first to combine the power of genetic patient selection and immunotherapy, evaluating patients with STK11 mutant cancers in a trial combining TNG260 and a checkpoint inhibitor. The FDA cleared the IND application for TNG260 in Q1 2023 and we expect to initiate a Phase 1/2 clinical trial in the second half of 2023.

BRCA 1/2-mut and other HRD+ cancers
IND filing mid-2023
Patients: BRCA 1/2-mut and other HRD+ cancers
Anticipated Milestones: IND filing mid-2023
Development Pathway

We are developing TNG348, a novel allosteric inhibitor of USP1 for treatment of BRCA1 and BRCA2-mutant and other HRD+ cancers. In vivo preclinical studies for TNG348 have shown single agent efficacy and combination benefit with PARP inhibitors in BRCA1, BRCA2-mutant and other HRD+ cell-line and patient derived xenografts, including those that are intrinsically resistant to PARP inhibition. These preclinical data further demonstrate that TNG348 is synergistic with PARP inhibition across a panel of human ovarian and breast cancer cell lines, including both PARP inhibitor sensitive and resistant models. Clinically, we expect TNG348 to have single agent activity in PARP inhibitor -naïve and PARP inhibitor-resistant BRCA1/2 mutant and other HRD+ cancers, and to synergize with PARP inhibitors. We expect to file an IND for this program in mid-2023.

Multiple synthetic lethal targets
Tumor suppressor gene loss

Gilead optioned and licensed targets not listed – learn more about our partnership below


Our global strategic collaboration with Gilead Sciences is focused on the discovery, development and commercialization of a pipeline of innovative targeted immune evasion therapies for patients with cancer. We are responsible for discovering and validating targets and for advancing select programs through clinical proof-of-concept. Gilead has options to worldwide rights on up to 15 of those targets. We retain the option to co-develop and co-promote the lead products for up to five of those programs in the U.S. with Gilead.

The collaboration, which was originally signed in 2018 and expanded in 2020, does not include our three lead programs. We retain all rights to those programs, along with the right to targets we have identified outside of the immune evasion space. We are committed to advancing the programs in our wholly owned pipeline into the clinic and beyond, as part of our mission to deliver the next generation of transformational targeted therapies to patients in need.

Tango Therapeutics Gilead

The Gilead logo is a trademark of Gilead Sciences, Inc.

We aim to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. We believe strategic collaborations with pharma and other biotech companies can help us achieve this goal and deliver more novel cancer drug targets and medicines to patients. Please reach out if you are interested in exploring ways to work together: bd@tangotx.com.

Learn more about the culture of innovation at Tango.Learn more about the culture of innovation at Tango.